AI-curated court updates, legal developments, and practice-area insights for Indian legal professionals.
Discusses commonly overlooked material event disclosures under SEBI LODR Regulation 30, providing practical compliance measures.
Explains Regulation 25 of SEBI LODR outlining the responsibilities and liabilities of independent directors in corporate governance.
The Calcutta High Court has permitted the Trinamool Congress to operate its frozen bank accounts under the supervision of a special officer, providing significant relief amid allegations of fund misuse.
Khushboo Sukhwani has been appointed as the General Counsel for Strategy & Investments at Signature Global. With a decade of experience in corporate law, she will oversee critical legal functions and governance matters.
ROC Ernakulam imposed a ₹20,000 penalty for incomplete allottee details in PAS-3, underscoring the importance of accurate disclosures in corporate filings.
SEBI has issued guidance to the Association of Mutual Funds in India (AMFI) to simplify the mutual fund transmission process upon the death of a unit holder, easing compliance for asset management companies.
The article explores the complexities faced by the Committee of Creditors under the Insolvency and Bankruptcy Code. It analyzes the provisions pertaining to Section 29A and Section 30(5).
The Central Drugs Standard Control Organization (CDSCO) is inviting comments on its policies regarding brand name extensions in the pharmaceuticals sector. This move aims to address ongoing concerns about the implications of such practices.
The Bombay High Court ruled that a developer cannot delay the conveyance deed to a society over future FSI issues. This decision reinforces the legal obligations of developers towards housing societies.
The CDSCO's recent notice invites comments on brand name extension practices in the pharmaceutical industry, signalling potential regulatory reforms.
The Central Drugs Standard Control Organization (CDSCO) is requesting feedback on brand name extension practices in the pharmaceutical industry, signaling a potential review of longstanding industry norms.
The Central Drugs Standard Control Organization (CDSCO) is inviting stakeholder comments on its policies regarding brand name extensions in the pharmaceutical sector. This move could lead to crucial changes in the practice of branding in the industry.
RBI clarifies FLA Return applicability and the filing process via FLAIR, with a late fee of ₹7,500. The due date for filing is set for July 31, 2026.